References
- Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med. 2005;165(11):1280–1285.
- Mott S, Poole J, Kenrick M. Physical and chemical restraints in acute care: their potential impact on the rehabilitation of older people. Int J Nurs Pract. 2005;11(3):95–101.
- Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA division of geriatric medicine. Arch Intern Med. 1991;151(9):1825–1832.
- Lövheim H, Sandman PO, Kallin K, et al. Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. Int Psychogeriatr. 2006;18(4):713–726.
- Bronskill SE, Anderson GM, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc. 2004;52(5):749–755.
- Gurwitz JH, Field TS, Judge J, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005;118(3):251–258.
- Budnitz DS, Pollock DA, Weidenbach KN, et al. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858–1866.
- Vigen CL, Mack WJ, Keefe RS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168(8):831–839.
- Hartikainen S, Lönnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci. 2007;62(10):1172–1181.
- Huybrechts KF, Schneeweiss S, Gerhard T, et al. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc. 2012;60(3):420–429.
- Jeste DV, Blazer D, Casey D, et al. ACNP White paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957–970.
- Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly. JAMA. 2005;293(20):2462.
- CMS. National Partnership to Improve Dementia Care in Nursing Homes: Antipsychotic Medication Use Data Report. January 22, 2021; [cited 2021 July 17]. Available from: https://www.cms.gov/files/document/antipsychotic-medication-use-data-report-2020q2-updated-01222021.pdf.
- Rubino A, Sanon M, Ganz ML, et al. Association of the US food and drug administration antipsychotic drug boxed warning with medication use and health outcomes in elderly patients with dementia. JAMA Netw Open. 2020;3(4):e203630.
- Orsolin L,I, Tomasetti C, Valchera A, et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016;15(10):1329–1347.
- Harris DA, Maclagan LC, Iaboni A, et al. Potential unintended consequences of antipsychotic reduction in Ontario nursing homes [published online ahead of print, 2022 Feb 7]. J Am Med Dir Assoc. 2022;2022:S1525-8610(22)00019-6.
- Dorsey ER, Rabbani A, Gallagher SA, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96–103.
- Beeber AS, Zimmerman S, Wretman CJ, et al. Potential side effects and adverse events of antipsychotic use for residents with dementia in assisted living: implications for prescribers, staff, and families. J Appl Gerontol. 2022;41(3):798–805.
- Rashid N, Abler V, Andes S, et al. Real-world medication treatment patterns for long-term care residents with Dementia-Related psychosis. Gerontol Geriatr Med. 2021;7:23337214211016565.
- Thomas K, Gebeloff R, Silver-Greenberg J. Phony diagnoses hide high rates of drugging at nursing homes. The New York Times. [Published 2021 Sep11; cited 2021 Nov 30]. Available from: https://www.nytimes.com/2021/09/11/health/nursing-homes-schizophrenia-antipsychotics.html.